RegCell raises $44M Series A to move Nobel-winning Treg science to the clinic
What's the deal? RegCell, an Emeryville, California biotech co-founded by Nobel laureate Shimon Sakaguchi, has closed US$28.5M Series A led by Playground GlobalDealroom has a profile for this one. Try Dealroom →. Alongside the round, it secured roughly $22 million in non-dilutive funding from Japan's Agency for Medical Research and Development (AMEDDealroom has a profile for this one. Try Dealroom →), for US$42.7M total.
What's the endgame? RegCell is developing therapies to restore immune tolerance in autoimmune disease. Its platform converts disease-causing T cells into stable, epigenetically reprogrammed regulatory T cells (Tregs) — the immune cells Sakaguchi discovered.
The approach targets the source of disease rather than broadly suppressing the immune system, the standard for autoimmune conditions for decades. Existing treatments can leave patients exposed to serious infections, cardiac toxicity, and secondary cancers.
Who's backing it? New investors Global BrainDealroom has a profile for this one. Try Dealroom →, Mitsui ChemicalsDealroom has a profile for this one. Try Dealroom →, LG Technology VenturesDealroom has a profile for this one. Try Dealroom →, Alumni Ventures, and Medical Incubator JapanDealroom has a profile for this one. Try Dealroom → joined the round, with support from existing backers including Fast Track InitiativeDealroom has a profile for this one. Try Dealroom → and UTECDealroom has a profile for this one. Try Dealroom →. Playground Global general partner Jory Bell joins RegCell's board.
What's the money for? RegCell plans to push its epigenetic reprogramming platform into clinical-stage development across multiple autoimmune indications, including myasthenia gravis, rheumatoid arthritis, and ulcerative colitis.
The AMED grant — RegCell's second — brings the agency's total non-dilutive commitment to about $59.3 million. It will fund a second-generation platform and an additional Phase 2 proof-of-concept study.
Why now? "For decades, my research has centered on the question of how the immune system governs itself," Sakaguchi said. The financing carries his roughly 50-year body of work toward patients for the first time.
The signal: At $44 million, RegCell's round sits in the top 0.2% of all Series A rounds ever recorded for health startups in Japan. It reflects rising investor appetite for Treg-based therapies aiming to reset the immune system rather than simply manage symptoms.
Read more: endpoints.news, businesswire.com
Image credit: Generated with Gemini
